课题基金 / 基金详情

Uric Acid and Hypertension in African-Americans

Uric Acid and Hypertension in African-Americans
非裔美国人的尿酸和高血压
批准号:
7413657
负责人:
MARK S. SEGAL
金额:
$67.16万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-08-01 至 2011-04-30

项目摘要

项目成果

MARK S. SEGAL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Thiazide diuretics are associated with many metabolic side effects including hyperuricemia, gout, insulin resistance, and hyperlipidemia. These very conditions are already highly prevalent in African-Americans. We and others have generated a large body of epidemiologic, animal model, cell culture, and preliminary data in patients that suggests that uric acid is itself a mediator of hypertension, endotheliai dysfunction, and systemic inflammation. In our animal models elevated uric acid leads to increased blood pressure (BP) and lowering uric acid decreases BP. Furthermore, our study of hypertensive young adults suggests that allopurinol treatment leads to a decrease in uric acid associated with a lower BP. Our hypothesis is that thiazide-induced hyperuricemia decreases the efficacy of thiazides in controlling BP, leads to endothelial dysfunction, and increases the incidence of insulin resistance and impaired glucose tolerance. This hypothesis will be tested in a randomized double-blind placebo-controlled 2x2 factorial clinical trial of 8- week duration in which a total of 300 African-Americans patients with stage 1 hypertension (BP: 140-159/90- 99 mm Hg) will be assigned to one of four regimens: 1) a thiazide-like diuretic, chlorthalidone 25 mg/day, and a xanthine oxidase inhibitor, allopurinol; 2) chlorthalidone 25 mg/day and placebo; 3) placebo or 4) allopurinol. All subjects will receive a low-sodium diet. Our hypothesis predicts that lowering uric acid will enhance BP control, prevent endothelial dysfunction, reduce systemic inflammation, improve g.ucose tolerance and reduce hyperinsulinemia. In Aim 1 we test the hypothesis that prevention of chlorthalidone - induced hyperuricemia with allopurinol results in improved BP control. In Aim 2 we test the hypothesis that prevention of chlorthalidone-induced increase in serum uric acid by allopurinol improves endothelial function and reduces systemic inflammation. In Aim 3 we test the hypothesis that prevention of chlorthalidone induced hyperuricemia with allopurinol improves renal blood flow and GFR and prevents microalbumineria.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s10895-013-1224-8
发表时间: 2013-09
期刊: JOURNAL OF FLUORESCENCE
影响因子: 2.7
作者: [Beem, Elaine, Segal, Mark S.]
通讯作者: Segal, Mark S.
The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic.
添加别嘌呤醇对接受噻嗪类利尿剂治疗的非裔美国人血压控制的影响。
DOI: 10.1016/j.jash.2015.05.009
发表时间: 2015
期刊: Journal of the American Society of Hypertension : JASH
影响因子: --
作者: [Segal,MarkS, Srinivas,TitteR, Mohandas,Rajesh, Shuster,JonathanJ, Wen,Xuerong, Whidden,Elaine, Tantravahi,JogiRaju, Johnson,RichardJ]
通讯作者: Johnson,RichardJ
Hydroxychloroquine for the Management of CVD in CKD
  • 批准号:
    10578651
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    MARK S. SEGAL
  • 依托单位:
Hydroxychloroquine for the Management of CVD in CKD
  • 批准号:
    10295157
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    MARK S. SEGAL
  • 依托单位:
Hydroxychloroquine for the Management of CVD in CKD
  • 批准号:
    9561551
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    MARK S. SEGAL
  • 依托单位:
Hydroxychloroquine for the Management of CVD in CKD
  • 批准号:
    10038795
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    MARK S. SEGAL
  • 依托单位:
海外基金